BioNTech (Mainz, DE / Cambridge, MA) sponsors 58 reconciled interventional Phase II and Phase III ClinicalTrials.gov studies (2018 to 2026), including 25 active protocols (19 recruiting now), 26 completed protocols, and 0 all-time original FDA Drugs@FDA NDA and BLA approvals.